Pharmaceutical Company Payments to U.S. Physicians: A Guide to the 2025 CMS Data
Pharmaceutical-company payment comparisons depend on three decisions: which reporting entities qualify as pharmaceutical companies, which physician recipients are included, and which payment category is measured. CMS's national Open Payments totals provide context, but they do not by themselves establish a pharmaceutical-company ranking or a company's share of physician payments.
This guide focuses on Program Year 2025 general payments and explains how to assess a company comparison. It does not name a Top 10 without a verified calculation. The aim is to make the comparison useful to researchers and pharmaceutical analysts while keeping its claims aligned with its population.
Table of contents
- Understand what the published total measures
- Define the company population
- Keep company and product comparisons separate
- Build a comparable company table
- Interpret the result without overstating it
- Frequently asked questions
- Sources
Understand what the published total measures
CMS reports $3.92 billion in general payments for Program Year 2025. The amount covers a broader population than pharmaceutical manufacturers paying U.S. physicians. It should not be presented as that subgroup's spending or used as the denominator for its company shares.
General payments are payments or transfers of value outside a research agreement or protocol. Research payments and ownership or investment interests are separate categories. A payment may be direct, indirect, or designated for another party; it is not necessarily cash received personally by a physician.
Program Year 2025 concerns transfers made during 2025, with annual publication in 2026. Compare the payment period, not simply the year displayed on a release page.
Define the company population
The term “reporting entity” is broader than “pharmaceutical company.” Open Payments includes applicable manufacturers and group purchasing organizations, and covered products extend beyond drugs and biological products to devices and medical supplies.
One defensible company-based approach is to include reporting entities with documented drug or biological-product manufacturing activity during the period. Exclude device-only and GPO-only entities. Treat this as an analyst-defined rule, not an official CMS pharma classification.
Keep the evidence for each entity's inclusion consistent. A recognizable name, a present-day corporate website, or ownership by a pharmaceutical parent does not automatically establish the business activity of every reporting affiliate during 2025.
The unit of comparison matters too. A reporting-entity ranking and a consolidated corporate-group ranking can produce different results. If subsidiaries are combined, document the group membership, ownership period, and treatment of changes during the year. Otherwise, preserve each reporting entity's identifier and reported name.
Keep company and product comparisons separate
| Comparison | What is included | Appropriate description |
|---|---|---|
| Company-based | Eligible physician general payments from qualifying reporting entities | Payments from the defined company group |
| Product-associated | Eligible records that meet a stated drug or biological-product association rule | Payments associated with the defined products |
| Consolidated corporate group | Payments combined using a documented ownership mapping | Payments attributed to the defined corporate groups |
A mixed drug-and-device manufacturer illustrates the difference. Counting all its eligible physician general payments can include device-related and product-unspecified records. The resulting company total is not drug-specific spending.
A product-associated comparison needs its own inclusion and allocation rules. A record that names several products does not reveal how its total amount should be divided among them.
Hypothetical example: One $500 payment record names two products. Counting $500 against each product and then adding the rows produces $1,000, although the source record reports only $500. Keep the payment once unless the analysis uses an explicit, defensible allocation method. The example is arithmetic, not a finding about any company.
Build a comparable company table
A useful company table should make its scope visible before readers reach the first rank.
Recipients. Use the CMS physician categories selected for the study, and state whether the population covers all CMS-defined physician types or a narrower MD/DO group. Exclude teaching hospitals and nonphysician practitioners when the question concerns physicians.
Geography. Apply a recipient-address rule. For example, a study can include physicians with reported practice or business addresses in the 50 states and DC. Do not substitute the manufacturer's location for the recipient's geography.
Payment records. Use one release snapshot, count each eligible payment record once, and resolve repeated record identifiers before summing dollars. Combining successive refreshes without resolving repeated records can duplicate the same disclosures.
Company shares. Divide each company's eligible dollars by total eligible dollars for the same company and physician population. The program-wide general-payment total is a different denominator.
Missing information. Disclose the handling of unresolved company identities, recipient classifications, addresses, and identifiers. A missing or unclassified record should not silently become an eligible pharmaceutical payment.
Ordering. Sort unrounded totals. If equal totals share a rank, explain the display rule and show every company tied at the cutoff when using that policy.
These decisions are part of the result's meaning. Two tables can both reproduce their own calculations correctly and still answer different questions because their company grouping or product rules differ.
Interpret the result without overstating it
A company payment total measures disclosed transfers of value within a defined scope. It does not measure pharmaceutical sales, Medicare drug expenditure, market share, or clinical quality.
The mix of payment categories can make apparently similar totals very different. Consulting fees, food and beverage, and royalty payments represent different reported relationships. Examine the nature-of-payment categories alongside an overall total before drawing a business conclusion.
For an individual company, use the CMS search and exploration tools to check the payment year, reporting entity, recipient population, and payment categories. A single company profile can help answer a specific question; a national ranking additionally requires complete, comparable coverage of every eligible company.
Payment disclosures alone do not establish improper conduct or show that a payment changed prescribing. Those conclusions require evidence beyond the payment amount.
Frequently asked questions
Which pharmaceutical company paid physicians the most in 2025?
This guide does not report a calculated leader. The answer depends on a verified company classification, physician and geographic filters, and a complete comparison for the selected payment year.
Can all payments from a pharmaceutical parent be combined?
They can be combined in a documented corporate-group analysis, but that is a different unit from the reporting entities in CMS records. Do not silently substitute one for the other.
Does a payment connected with a drug show that the recipient prescribed it?
No. A reported product association describes the disclosure record. Establishing prescribing activity requires separate prescribing evidence and a validated link.